NCT02277444 – A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy Posted on April 29, 2025 by Molly Willeford -
NCT03253796 – Golimumab Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) Posted on October 14, 2024 by Jessica Ritchie -
NCT00367237 – A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis Posted on May 15, 2024 by Jessica Ritchie -
NCT00051623 – A Multicenter, Randomized, Double-blind Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) for the Treatment of Patients With Psoriatic Arthritis Posted on May 9, 2024 by Jessica Ritchie -
NCT03796858 – Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNFα) Therapy Posted on May 9, 2024 by Jessica Ritchie -
NCT02319759 – A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis Posted on May 9, 2024 by Jessica Ritchie -
NCT03158285 – A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Posted on May 9, 2024 by Jessica Ritchie -
NCT03162796 – A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents Posted on May 9, 2024 by Jessica Ritchie -
NCT03628924 – A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa Posted on August 16, 2023 by Jessica Ritchie -
The YODA Project